Eyevensys appoints Dr. Francesco Sinigaglia as Chairman of the Board
Paris (France), XX 2015 – Eyevensys, a private biotechnology company developing its proprietary EyeCET platform, the first non-viral technology that allows a safe local sustained production of therapeutic proteins in the eye to address a wide range of ophthalmic diseases, today announced the appointment of Dr. Francesco Sinigaglia as Chairman of the Board of Directors with immediate effect.
Dr. Sinigaglia is a senior pharma professional and a serial entrepreneur. He is currently a member of the Executive Board of Dompé, and founder and Chief Operating Officer of Anabasis Srl, a biotech company specialised in the development of innovative therapies for the eye that was acquired by the Dompé Group in 2012. He has over 30 years of industry experience in the healthcare sector, in particular at Roche headquarters in Basel. In 2002 he co-founded Bioxell SpA, a biotech company he led for 8 years and took to the Zurich stock exchange in 2006.
“We are delighted to welcome Francesco to the Board of Eyevensys, said Raffy Kazandjian, CEO of Eyevensys. “I am confident that Francesco will provide the Company with the insights and guidance we need to develop our unique EyeCET platform and pipeline strategy.”